Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients

Hormone and Metabolic Research

Volumn 41, Issue 12, 2009, Pages 893-898

  Fogari, R ^a   Zoppi, A ^a   Ferrari, I ^a   Mugellini, A ^a   Preti, P ^a   Lazzari, P ^a   Derosa, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

AT 1 blockers; Body weight; Hyperinsulinemic clamp; Hypertension; Insulin resistance; Sartans

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE INFUSION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; OBESITY; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ACRYLATES; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD GLUCOSE; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; INSULIN; MALE; MIDDLE AGED; OVERWEIGHT; THIOPHENES;

EID: 71849091557     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0029-1237359     Document Type: Article

References (54)

1. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dieta WH. The disease burden associated with overweight and obesity. JAMA 1999 282 1523-1529
2. Brown CD, Higgins M, Donato KA. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000 8 605-619
3. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH, American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss. An update of the 1997 American Heart Association Scientific Statement on obesity and heart disease from the Obesity Committee of the Obesity Committee of the Council on Nutrition, Physical Activity and Metabolism. Circulation 2006 113 898-918
4. Richards RJ, Thakur V, Reisin E. Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment. J Hum Hypertens 1996 10 (Suppl 3) S59-S64
5. Rocchini AP. Obesity hypertension. Am J Hypertens 2002 15 50S-52S
6. Dentali F, Sharma AM, Douketis JD. Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Res 2005 7 330-336
7. Wenzel UO, Krebs C. Treatment of arterial hypertension in obese patients. Contrib Nephrol 2006 151 230-242
8. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 995-1003 (Pubitemid 34286536)
9. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin Angiotensin System. Drugs 2004 64 2537-2565
10. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004 363 2049-2051
11. Ostergren J. Renin-angiotensin system blockade in the prevention of diabetes. Diabetes Res Clin Pract 2007 73 (Suppl 3) S13-S21
12. Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. ACE-inhibitor improve insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002 40 329-334
13. Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system. Am J Hypertens 2008 21 852-859
14. Kintscher U, Foryst-Ludwig A, Unger T. Inhibitin angiotensin type 1 receptors as a target for diabetes. Expert Opin Ther Targets 2008 12 1257-1263
15. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type-1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004 109 2054-2057
16. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005 54 3442-3452
17. Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPAR- by angiotensin II type-1 receptor antagonists. Vascular Pharmacology 2006 45 154-162
18. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomised, double-blind, placebo-controlled 12-month study. Hypertens Res 2004 27 457-464 (Pubitemid 39157547)
19. Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005 28 757-758
20. Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Diabetes Care 2005 28 498
21. Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005 4 6
22. Derosa G, Cicero AF, DAngelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-α Hypertens Res 2006 29 849-856
23. Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin-resistant, hypertensive patients. J Endocrinol Invest 2006 29 957-961 (Pubitemid 46344228)
24. Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 2007 30 49-53
25. Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 2007 24 146-153
26. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001 61 1501-1529 (Pubitemid 32783749)
27. Plosker GL, Foster RH. Eprosartan: a review of its use in the management of hypertension. Drugs 2000 60 177-201
28. De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979 237 214-223
29. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 1987 317 350-357
30. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diab Med 1999 16 716-730
31. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972 8 260-266
32. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978 15 121-130
33. Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU (ed) Methods of Enzymatic Analysis, 2nd English ed New York: Academic Press Inc. 1974 18-31
34. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955 34 1345-1353
35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972 18 499-502
36. Senn SJ. Cross-over trials in clinical research New York: Wiley 1993
37. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998 351 1755-1762 (Pubitemid 28269185)
38. Heart Outcomes Prevention Evaluation Study (HOPE) Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000 342 145-153
39. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003 17 305-322
40. Motley ED, Eguchi K, Gardner, Hicks AL, Reynolds CM, Frank GD, Mifune M, Ohba M, Eguchi S. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension 2003 41 775-780
41. Picard F, Auwerx J. PPAR-gamma and glucose homeostasis. Annu Rev Nutr 2002 22 167-197
42. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW, PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008 359 1225-1237
43. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B, HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001 286 1882-1885
44. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007 369 201-207
45. The DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006 355 1551-1562
46. Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S, for the TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of Telmisartan on Renal Outcomes: A Randomized Trial. Ann Intern Med 2009 151 1-10
47. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004 351 1106-1118
48. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000 14 S73-S86
49. Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 2006 24 1809-1816
50. Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996 1302 93-109
51. Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Böhm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U. Liver-specific PPAR-target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008 57 1405-1413
52. Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002 90 703-710
53. Walcher D, Hess K, Heinz P, Petscher K, Vasic D, Kintscher U, Clemenz M, Hartge M, Raps K, Hombach V, Marx N. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension 2008 51 259-266
54. Scalera F, Martens-Lobenhoffen J, Buckowska A, Lendeckel U, Tager M, Bode-Boger SM. Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system, role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor gamma signalling during endothelial aging. Hypertension 2008 51 696-703